Published in Prostate on September 01, 2007
High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol (2009) 2.97
Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res (2014) 1.65
Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci U S A (2008) 1.53
Vitamin D pathway gene variants and prostate cancer prognosis. Prostate (2010) 1.20
How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer?: An examination using Hill's criteria for causality. Dermatoendocrinol (2009) 1.13
Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. Dermatoendocrinol (2012) 1.03
Seasonal variations of cancer incidence and prognosis. Dermatoendocrinol (2010) 0.98
Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control (2010) 0.91
Vitamin d, sunlight and prostate cancer risk. Adv Prev Med (2011) 0.87
Seasonality pattern of breast, colorectal, and prostate cancer is dependent on latitude. Med Sci Monit (2014) 0.84
The role of the bone microenvironment in skeletal metastasis. J Bone Oncol (2012) 0.79
Vitamin D may reduce prostate cancer metastasis by several mechanisms including blocking Stat3. Am J Pathol (2008) 0.78
Similarities in solar ultraviolet irradiance and other environmental factors may explain much of the family link between uveal melanoma and other cancers. Fam Cancer (2010) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control (2004) 2.04
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
Statins and prostate cancer risk: a case-control study. Am J Epidemiol (2005) 1.90
The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res (2009) 1.86
Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol (2005) 1.85
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology (2006) 1.75
Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: potential for enhanced topical photodynamic therapy. J Control Release (2008) 1.65
On the selectivity of 5-aminolevulinic acid-induced protoporphyrin IX formation. Curr Med Chem Anticancer Agents (2004) 1.65
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol (2009) 1.62
The importance of the depth distribution of melanin in skin for DNA protection and other photobiological processes. J Photochem Photobiol B (2006) 1.61
Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci U S A (2008) 1.53
Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer (2005) 1.49
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med (2011) 1.48
Advanced penile carcinoma. J Urol (2003) 1.47
Interest in physician-assisted suicide among Oregon cancer patients. J Clin Ethics (2006) 1.45
[The photobiology of vitamin D--a topic of renewed focus]. Tidsskr Nor Laegeforen (2006) 1.45
Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J Clin Endocrinol Metab (2012) 1.44
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
[Rhythms, depressions and light]. Tidsskr Nor Laegeforen (2006) 1.40
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. Oncology (Williston Park) (2016) 1.38
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol (2007) 1.32
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Estimated benefit of increased vitamin D status in reducing the economic burden of disease in western Europe. Prog Biophys Mol Biol (2009) 1.26
HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem (2011) 1.25
Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study. PLoS One (2012) 1.23
Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer (2007) 1.21
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate (2010) 1.14
The seasonality of pandemic and non-pandemic influenzas: the roles of solar radiation and vitamin D. Int J Infect Dis (2010) 1.13
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer (2008) 1.10
Changes in risk of death from breast cancer with season and latitude: sun exposure and breast cancer survival in Norway. Breast Cancer Res Treat (2006) 1.08
Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer (2008) 1.08
Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci (2007) 1.05
Ultraviolet radiation and malignant melanoma. Adv Exp Med Biol (2008) 1.05
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 1.04
Solar radiation, vitamin D and survival rate of colon cancer in Norway. J Photochem Photobiol B (2005) 1.04
Microneedle arrays permit enhanced intradermal delivery of a preformed photosensitizer. Photochem Photobiol (2008) 1.03
Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: a possible role of sun-induced Vitamin D. J Steroid Biochem Mol Biol (2007) 1.03
Ultraviolet photodegradation of folic acid. J Photochem Photobiol B (2005) 1.03
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol (2010) 1.02
Sun exposure and cancer survival in Norway: changes in the risk of death with season of diagnosis and latitude. Adv Exp Med Biol (2008) 1.02
The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells. Clin Cancer Res (2008) 1.01
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res (2010) 1.01
Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res (2007) 1.00
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urol Oncol (2011) 0.99
Metabolic changes in urine during and after pregnancy in a large, multiethnic population-based cohort study of gestational diabetes. PLoS One (2012) 0.98
Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. Magn Reson Med (2012) 0.96
HIF1α protein stability is increased by acetylation at lysine 709. J Biol Chem (2012) 0.96
In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res (2005) 0.95
Colon cancer: prognosis for different latitudes, age groups and seasons in Norway. J Photochem Photobiol B (2007) 0.94
Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol (2006) 0.93
Seasonal variation of 1,25-dihydroxyvitamin D and its association with body mass index and age. J Steroid Biochem Mol Biol (2009) 0.93
Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res (2014) 0.93
Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) (2012) 0.93
A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer. Int J Radiat Oncol Biol Phys (2003) 0.93
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest New Drugs (2014) 0.92
Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy. Lasers Med Sci (2004) 0.92
Androgen deprivation impairs memory in older men. Behav Neurosci (2005) 0.91
Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo. Photochem Photobiol Sci (2002) 0.91
Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control (2010) 0.91
Cell membrane water exchange effects in prostate DCE-MRI. J Magn Reson (2012) 0.91
The effect of sub-lethal ALA-PDT on the cytoskeleton and adhesion of cultured human cancer cells. Biochim Biophys Acta (2004) 0.91
Beneficial effects of UV radiation other than via vitamin D production. Dermatoendocrinol (2012) 0.91
Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Release (2005) 0.90
Vitamin D status in Norwegian children and adolescents with excess body weight. Pediatr Diabetes (2010) 0.89
Fluorescent particles in the antibody solution result in false TF- and CD14-positive microparticles in flow cytometric analysis. Cytometry A (2011) 0.89
In vitro and in vivo photosensitization by protoporphyrins possessing different lipophilicities and vertical localization in the membrane. Photochem Photobiol (2007) 0.88
Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology (2007) 0.88
Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int (2005) 0.88
Radiosensitization of tumours by porphyrins. Cancer Lett (2005) 0.88
Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. Prostate (2013) 0.88